Triple G-Agonists (Retatrutide and Beyond): A Continued Home Run for Obesity in 2025
Introduction The buzz around hormone-based obesity therapies, ignited at the 2023 American Diabetes Association (ADA) Scientific Sessions, has only intensified by 2025. Retatrutide, Eli Lilly's triple-hormone-receptor agonist, led the charge with phase 2 results showing 24% mean weight loss over 48 weeks in non-diabetic adults with obesity ( aestheticsadvisor.com ). Now in phase 3 (TRIUMPH program), with topline data expected Q4 2025 and potential FDA approval by 2027, retatrutide exemplifies the triple G-agonist class's promise. Meanwhile, competitors like Novo's UBT251 (15.4% loss in 12 weeks phase 1b) and oral candidates from Protagonist Therapeutics signal a transformative era, potentially outpacing dual agonists like tirzepatide. Source: eClinicalMedicine 2024 Hormonal Responses and Background Nutrient sensing triggers a symphony of hormones—insulin, GLP-1, GIP, PYY, amylin—that curb appetite, boost insulin, and ramp up metabolism. GLP-1 agonists revolutionized T2D ...